Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 426

1.

The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-Versus-Host Disparity Is Associated with Increased Acute Graft-Versus-Host Disease in Haploidentical Transplantation with Post-Transplant Cyclophosphamide.

Rimando J, Slade M, DiPersio JF, Westervelt P, Gao F, Liu C, Romee R.

Biol Blood Marrow Transplant. 2019 Sep 26. pii: S1083-8791(19)30635-4. doi: 10.1016/j.bbmt.2019.09.024. [Epub ahead of print]

PMID:
31563575
2.

GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma.

Crees ZD, Stockerl-Goldstein K, Vainstein A, Chen H, DiPersio JF.

Future Oncol. 2019 Sep 9. doi: 10.2217/fon-2019-0380. [Epub ahead of print]

PMID:
31495201
3.

A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.

Tuscano JM, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev AA, Beaven A, DiPersio JF, Popplewell L, Chen R, Kirschbaum M, Schroeder MA, Newman EM.

Clin Cancer Res. 2019 Sep 3. doi: 10.1158/1078-0432.CCR-19-0438. [Epub ahead of print]

PMID:
31481504
4.

The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation.

Jacobs MT, Olson M, Ferreira BP, Jin R, Hachem R, Byers D, Witt C, Ghobadi A, DiPersio JF, Pusic I.

Am J Transplant. 2019 Aug 25. doi: 10.1111/ajt.15579. [Epub ahead of print]

PMID:
31446673
5.

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y.

Biol Blood Marrow Transplant. 2019 Aug 22. pii: S1083-8791(19)30529-4. doi: 10.1016/j.bbmt.2019.08.015. [Epub ahead of print] Review.

PMID:
31446199
6.

A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.

Ghobadi A, Fiala MA, Rettig M, Schroeder M, Uy GL, Stockerl-Goldstein K, Westervelt P, Vij R, DiPersio JF.

Clin Lymphoma Myeloma Leuk. 2019 May 2. pii: S2152-2650(19)30019-9. doi: 10.1016/j.clml.2019.04.017. [Epub ahead of print]

PMID:
31358485
7.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Bone Marrow Transplant. 2019 May 15. doi: 10.1038/s41409-019-0451-2. [Epub ahead of print]

PMID:
31092900
8.

Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells.

Karpova D, Rettig MP, Ritchey J, Cancilla D, Christ S, Gehrs L, Chendamarai E, Evbuomwan MO, Holt M, Zhang J, Abou-Ezzi G, Celik H, Wiercinska E, Yang W, Gao F, Eissenberg LG, Heier RF, Arnett SD, Meyers MJ, Prinsen MJ, Griggs DW, Trumpp A, Ruminski PG, Morrow DM, Bonig HB, Link DC, DiPersio JF.

J Clin Invest. 2019 May 14;129(7):2745-2759. doi: 10.1172/JCI124738.

9.

Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia.

Ghobadi A, Miller CA, Li T, O'Laughlin M, Lee YS, Ali M, Westervelt P, DiPersio JF, Wartman L.

Haematologica. 2019 Aug;104(8):e373-e375. doi: 10.3324/haematol.2019.217794. Epub 2019 Mar 28. No abstract available.

10.

Immune Escape of AML Cells after Transplantation. Reply.

Christopher M, DiPersio JF, Ley TJ.

N Engl J Med. 2019 Mar 28;380(13):1290. doi: 10.1056/NEJMc1900424. No abstract available.

PMID:
30917273
11.

Dynamic host immune response in virus-associated cancers.

Cao S, Wylie KM, Wyczalkowski MA, Karpova A, Ley J, Sun S, Mashl RJ, Liang WW, Wang X, Johnson K, DiPersio JF, Gay H, Ratner L, Chen F, Adkins DR, Ding L.

Commun Biol. 2019 Mar 22;2:109. doi: 10.1038/s42003-019-0352-3. eCollection 2019.

12.

Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells.

Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM.

Blood Adv. 2019 Mar 26;3(6):875-883. doi: 10.1182/bloodadvances.2018027599.

13.

Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia.

Abboud R, Han SY, Duncavage EJ, Cashen AF, Shirai CL, Welch JS, DiPersio JF, Abboud CN.

Haematologica. 2019 Apr;104(4):e170-e173. doi: 10.3324/haematol.2018.209478. Epub 2019 Feb 7. No abstract available.

14.

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. Review.

15.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e76-e85. doi: 10.1016/j.bbmt.2018.12.068. Epub 2018 Dec 18.

PMID:
30576834
16.

HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.

Rimando J, Slade M, DiPersio JF, Westervelt P, Gao F, Liu C, Romee R.

Blood Adv. 2018 Dec 26;2(24):3590-3601. doi: 10.1182/bloodadvances.2018025437.

17.

CiTE antibody for AML.

Rettig MP, DiPersio JF.

Blood. 2018 Dec 6;132(23):2425-2427. doi: 10.1182/blood-2018-10-879668. No abstract available.

PMID:
30523124
18.

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD.

Ashami K, DiPersio JF, Choi J.

Oncotarget. 2018 Nov 6;9(87):35721-35722. doi: 10.18632/oncotarget.26291. eCollection 2018 Nov 6. No abstract available.

19.

Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation.

Alahmari B, Cooper M, Ziga E, Ritchey J, DiPersio JF, Choi J.

PLoS One. 2018 Nov 19;13(11):e0207609. doi: 10.1371/journal.pone.0207609. eCollection 2018.

20.

Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.

Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM, Helton NM, O'Laughlin M, Fronick CC, Fulton RS, Wilson RK, Wartman LD, Welch JS, Heath SE, Baty JD, Payton JE, Graubert TA, Link DC, Walter MJ, Westervelt P, Ley TJ, DiPersio JF.

N Engl J Med. 2018 Dec 13;379(24):2330-2341. doi: 10.1056/NEJMoa1808777. Epub 2018 Oct 31.

21.

Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

Duncavage EJ, Jacoby MA, Chang GS, Miller CA, Edwin N, Shao J, Elliott K, Robinson J, Abel H, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Brendel K, Saba R, Wartman LD, Christopher MJ, Pusic I, Welch JS, Uy GL, Link DC, DiPersio JF, Westervelt P, Ley TJ, Trinkaus K, Graubert TA, Walter MJ.

N Engl J Med. 2018 Sep 13;379(11):1028-1041. doi: 10.1056/NEJMoa1804714.

22.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.

Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE.

Blood Cancer J. 2018 Sep 3;8(9):88. doi: 10.1038/s41408-018-0122-3. No abstract available.

23.

Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.

Ferraro F, Gao F, Stockerl-Goldstein K, Westervelt P, DiPersio JF, Ghobadi A.

Leuk Res. 2018 Sep;72:86-91. doi: 10.1016/j.leukres.2018.07.024. Epub 2018 Jul 31. Review.

PMID:
30114560
24.

Integrative omics analyses broaden treatment targets in human cancer.

Sengupta S, Sun SQ, Huang KL, Oh C, Bailey MH, Varghese R, Wyczalkowski MA, Ning J, Tripathi P, McMichael JF, Johnson KJ, Kandoth C, Welch J, Ma C, Wendl MC, Payne SH, Fenyö D, Townsend RR, Dipersio JF, Chen F, Ding L.

Genome Med. 2018 Jul 27;10(1):60. doi: 10.1186/s13073-018-0564-z.

25.

Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.

Gooptu M, Kim HT, Chen YB, Rybka W, Artz A, Boyer M, Johnston L, McGuirk J, Shea TC, Jagasia M, Shaughnessy PJ, Reynolds CG, Fields M, Alyea EP, Ho VT, Glavin F, Dipersio JF, Westervelt P, Ritz J, Soiffer RJ.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2216-2223. doi: 10.1016/j.bbmt.2018.07.002. Epub 2018 Jul 10.

PMID:
30006305
26.

Transfer of Cell-Surface Antigens by Scavenger Receptor CD36 Promotes Thymic Regulatory T Cell Receptor Repertoire Development and Allo-tolerance.

Perry JSA, Russler-Germain EV, Zhou YW, Purtha W, Cooper ML, Choi J, Schroeder MA, Salazar V, Egawa T, Lee BC, Abumrad NA, Kim BS, Anderson MS, DiPersio JF, Hsieh CS.

Immunity. 2018 Jun 19;48(6):1271. doi: 10.1016/j.immuni.2018.05.011. No abstract available.

27.

Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation.

Huselton E, Slade M, Trinkaus KM, DiPersio JF, Westervelt P, Romee R.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2047-2055. doi: 10.1016/j.bbmt.2018.05.024. Epub 2018 May 24.

28.

Transfer of Cell-Surface Antigens by Scavenger Receptor CD36 Promotes Thymic Regulatory T Cell Receptor Repertoire Development and Allo-tolerance.

Perry JSA, Russler-Germain EV, Zhou YW, Purtha W, Cooper ML, Choi J, Schroeder MA, Salazar V, Egawa T, Lee BC, Abumrad NA, Kim BS, Anderson MS, DiPersio JF, Hsieh CS.

Immunity. 2018 May 15;48(5):923-936.e4. doi: 10.1016/j.immuni.2018.04.007. Epub 2018 May 8. Erratum in: Immunity. 2018 Jun 19;48(6):1271.

29.

Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.

Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, Broyer L, D'Asaro M, Matthes T, LeGallou S, Fest T, Tarte K, Clarke Hinojosa RK, Genescà Ferrer E, Ribera JM, Dey A, Bailey K, Fielding AK, Eissenberg L, Ritchey J, Rettig M, DiPersio JF, Kosco-Vilbois MH, Masternak K, Fischer N, Shang L, Ferlin WG.

Mol Cancer Ther. 2018 Aug;17(8):1739-1751. doi: 10.1158/1535-7163.MCT-17-1095. Epub 2018 May 9.

30.

Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.

Ghobadi A, Rettig MP, Holt MS, Ritchey JK, Kennerly K, Chendamarai E, Eissenberg L, DiPersio JF.

Blood. 2018 Jun 7;131(23):2594-2596. doi: 10.1182/blood-2017-10-811620. Epub 2018 Apr 25. No abstract available.

31.

Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease.

Choi J, Cooper ML, Staser K, Ashami K, Vij KR, Wang B, Marsala L, Niswonger J, Ritchey J, Alahmari B, Achilefu S, Tsunoda I, Schroeder MA, DiPersio JF.

Leukemia. 2018 Nov;32(11):2483-2494. doi: 10.1038/s41375-018-0123-z. Epub 2018 Apr 2.

32.

Pathogenic Germline Variants in 10,389 Adult Cancers.

Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Hucthagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ; Cancer Genome Atlas Research Network, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L.

Cell. 2018 Apr 5;173(2):355-370.e14. doi: 10.1016/j.cell.2018.03.039.

33.

A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1581-1589. doi: 10.1016/j.bbmt.2018.03.019. Epub 2018 Mar 27.

34.

Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow.

Bansal D, Vij K, Chang GS, Miller CA, DiPersio JF, Vij R, Heath SE, Westervelt P, Welch JS, Fehniger TA.

Haematologica. 2018 Jun;103(6):e270-e273. doi: 10.3324/haematol.2017.184168. Epub 2018 Mar 22. No abstract available.

35.

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.

White BS, Lanc I, O'Neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA Jr, Fiala M, King J, Ahmann GJ, DeRome M, Mardis ER, Vij R, DiPersio JF, Levy J, Auclair D, Tomasson MH.

Blood Cancer J. 2018 Mar 21;8(3):35. doi: 10.1038/s41408-018-0062-y.

36.

Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.

Jacoby MA, Duncavage EJ, Chang GS, Miller CA, Shao J, Elliott K, Robinson J, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Pusic I, Welch JS, Link DC, DiPersio JF, Westervelt P, Ley TJ, Graubert TA, Walter MJ.

JCI Insight. 2018 Mar 8;3(5). pii: 98962. doi: 10.1172/jci.insight.98962.

37.

An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.

Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, Rettig MP, Wang B, Eissenberg LG, Ghobadi A, Gehrs LN, Prior JL, Achilefu S, Miller CA, Fronick CC, O'Neal J, Gao F, Weinstock DM, Gutierrez A, Fulton RS, DiPersio JF.

Leukemia. 2018 Sep;32(9):1970-1983. doi: 10.1038/s41375-018-0065-5. Epub 2018 Feb 20.

38.

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS.

Blood. 2018 Jun 7;131(23):2515-2527. doi: 10.1182/blood-2017-12-823757. Epub 2018 Feb 20.

39.

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.

Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, Kaufman JL, McCarty JM, Vargo R, Cheverton PD, Struijs M, Bolwell B, DiPersio JF.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1187-1195. doi: 10.1016/j.bbmt.2018.01.039. Epub 2018 Feb 2.

40.

Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.

Wong TN, Miller CA, Jotte MRM, Bagegni N, Baty JD, Schmidt AP, Cashen AF, Duncavage EJ, Helton NM, Fiala M, Fulton RS, Heath SE, Janke M, Luber K, Westervelt P, Vij R, DiPersio JF, Welch JS, Graubert TA, Walter MJ, Ley TJ, Link DC.

Nat Commun. 2018 Jan 31;9(1):455. doi: 10.1038/s41467-018-02858-0.

41.

Acute graft-versus-host disease following lung transplantation in a patient with a novel TERT mutation.

Brestoff JR, Vessoni AT, Brenner KA, Uy GL, DiPersio JF, Blinder M, Witt CA, Byers DE, Hachem RR, Truclock EP, Early DS, Anadkat MJ, Musiek A, Javidan-Nejad C, Balfe DM, Rosman IS, Liu C, Zhang L, Despotis GJ, Ruzinova MB, Sehn JK, Amarillo I, Heusel JW, Swat W, Kim BS, Wartman LD, Yusen RD, Batista LFZ.

Thorax. 2018 May;73(5):489-492. doi: 10.1136/thoraxjnl-2017-211121. Epub 2018 Jan 30.

42.

Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance.

van den Brink M, Uhrberg M, Jahn L, DiPersio JF, Pulsipher MA.

Bone Marrow Transplant. 2018 Aug;53(8):949-959. doi: 10.1038/s41409-017-0078-0. Epub 2018 Jan 24. Review.

PMID:
29367714
43.

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.

Khoury HJ, Langston AA, Kota VK, Wilkinson JA, Pusic I, Jillella A, Bauer S, Kim AS, Roberts D, Al-Kadhimi Z, Bodo I, Winton E, Arellano M, DiPersio JF.

Bone Marrow Transplant. 2018 Jul;53(7):826-831. doi: 10.1038/s41409-017-0081-5. Epub 2018 Jan 24.

44.

Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer.

Kotagiri N, Cooper ML, Rettig M, Egbulefu C, Prior J, Cui G, Karmakar P, Zhou M, Yang X, Sudlow G, Marsala L, Chanswangphuwana C, Lu L, Habimana-Griffin L, Shokeen M, Xu X, Weilbaecher K, Tomasson M, Lanza G, DiPersio JF, Achilefu S.

Nat Commun. 2018 Jan 18;9(1):275. doi: 10.1038/s41467-017-02758-9.

45.

The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.

Schroeder MA, Choi J, Staser K, DiPersio JF.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1125-1134. doi: 10.1016/j.bbmt.2017.12.797. Epub 2017 Dec 28. Review.

46.

OMIP-042: 21-color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral blood.

Staser KW, Eades W, Choi J, Karpova D, DiPersio JF.

Cytometry A. 2018 Feb;93(2):186-189. doi: 10.1002/cyto.a.23303. Epub 2017 Dec 30. No abstract available.

47.

Diabetes mellitus as a poor mobilizer condition.

Fadini GP, DiPersio JF.

Blood Rev. 2018 May;32(3):184-191. doi: 10.1016/j.blre.2017.11.002. Epub 2017 Nov 8. Review.

PMID:
29132746
48.

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.

Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS.

Cancer Med. 2017 Dec;6(12):2814-2821. doi: 10.1002/cam4.1231. Epub 2017 Oct 23.

49.

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB.

J Clin Oncol. 2017 Dec 20;35(36):4003-4011. doi: 10.1200/JCO.2017.75.8177. Epub 2017 Oct 17.

PMID:
29040031
50.

Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy.

Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Schroeder MA, Gao F, Romee R.

Bone Marrow Transplant. 2017 Dec;52(12):1623-1628. doi: 10.1038/bmt.2017.193. Epub 2017 Oct 16.

PMID:
29035393

Supplemental Content

Loading ...
Support Center